Beyond C, H, O, and N! analysis of the elemental composition of U.S. FDA approved drug architectures

Journal of Medicinal Chemistry

Volumn 57, Issue 23, 2014, Pages 9764-9773

  Smith, Brandon R ^a   Eastman, Candice M ^a   Njardarson, Jon T ^a  

^a University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE; BENDAMUSTINE; BROMINE; CARBON; CARDIOVASCULAR AGENT; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CHLORINE; CHLOROTRIANISENE; CYANOCOBALAMIN; ELEMENT; ETHCHLORVYNOL; FLUORINE; HYDROGEN; HYDROXOCOBALAMIN; IFOSFAMIDE; IODINE; MOMETASONE FUROATE; NATURAL PRODUCT; NITROGEN; OXYGEN; PHENOXYBENZAMINE; PHOSPHORUS; PIMECROLIMUS; PLATINUM; SULFUR; TACROLIMUS; TRANSITION ELEMENT; TRICHLORMETHIAZIDE; UNINDEXED DRUG; DRUG;

CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CHLORINATION; DIGESTIVE SYSTEM; DRUG APPROVAL; DRUG DISTRIBUTION; FOOD AND DRUG ADMINISTRATION; HYBRIDIZATION; REVIEW; SENSE ORGAN; SUBSTITUTION REACTION; CHEMISTRY; UNITED STATES;

CHLORINE; DRUG APPROVAL; FLUORINE; PHARMACEUTICAL PREPARATIONS; PHOSPHORUS; SULFUR; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84918563509     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501105n     Document Type: Review

References (27)

1. Ilardi, E. A.; Vitaku, E.; Njardarson, J. T. Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals to Reveal Opportunities for Drug Design and Discovery J. Med. Chem. 2014, 57, 2832-2842
2. The Njardarson Group. Disease Focused Pharmaceutical Posters. http://cbc.arizona.edu/njardarson/group/content/disease-focused-pharmaceutical-posters.
3. Kosjek, T.; Heath, E. Halogenated Heterocycles as Pharmaceuticals. In Halogenated Heterocycles; Iskra, J., Ed.; Springer: Berlin, 2012; Vol. 27, pp 219-246.
4. Hernandes, M. Z.; Cavalcanti, S. M. T.; Moreira, D. R. M.; de Azevedo, D. W.; Leite, A. C. L. Halogen Atoms in the Modern Medicinal Chemistry: Hints for the Drug Design Curr. Drug Targets 2010, 11, 303-314
5. Parisini, E.; Metrangolo, P.; Pilati, T.; Resnati, G.; Terraneo, G. Halogen Bonding in Halocarbon-Protein Complexes: A Structural Survey Chem. Soc. Rev. 2011, 40, 2267-2278
6. Wilcken, R.; Zimmermann, M. O.; Lange, A.; Joerger, A. C.; Boeckler, F. M. Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology J. Med. Chem. 2012, 56, 1363-1388
7. We have created a similar montage as a way to display the new drugs approved by the U.S. FDA in 2011: Njardarson, J. T. Pharmaceutical Structure Montages as Catalysts for Design and Discovery Future Med. Chem. 2012, 4, 951-954
8. Elliott, T. S.; Slowey, A.; Ye, Y.; Conway, S. J. The Use of Phosphate Bioisosteres in Medicinal Chemistry and Chemical Biology MedChemComm 2012, 3, 735-751
9. According to the National Cancer Institute (http://www.cancer.gov), these chemotherapy regimens do not have an official FDA approval; however, each individual molecular component is FDA approved.
10. This new chlorine focused pharmaceutical poster can be downloaded freely as a PDF file from a designated Web page: http://cbc.arizona.edu/njardarson/group/content/disease-focused-pharmaceutical-posters.
11. Clemons, P. A.; Bodycombe, N. E.; Carrinski, H. A.; Wilson, J. A.; Shamji, A. F.; Wagner, B. K.; Koehler, A. N.; Schreiber, S. L. Small Molecules of Different Origins Have Distinct Distributions of Structural Complexity That Correlate with Protein-Binding Profiles Proc. Natl. Acad. Sci. U.S. A. 2010, 107, 18787-18792
12. Topliss, J. G. Utilization of Operational Schemes for Analog Synthesis in Drug Design J. Med. Chem. 1972, 15, 1006-1011
13. Topliss, J. G. A Manual Method for Applying the Hansch Approach to Drug Design J. Med. Chem. 1977, 20, 463-469
14. Saha, P.; Debnath, C.; Bérubé, G. Steroid-Linked Nitrogen Mustards as Potential Anticancer Therapeutics: A Review J. Steroid Biochem. 2013, 137, 271-300
15. Bansal, R.; Acharya, P. C. Man-Made Cytotoxic Steroids: Exemplary Agents for Cancer Therapy Chem. Rev. 2014, 114, 6986-7005
16. Qin, J.; Chen, P. Bromine Pharmacokinetics and Pharmacodynamics Guangdong Weiliang Yuansu Kexue 2011, 18 (10) 1-21
17. Qin, J.; Chen, P. Bromine in Medicinal Research and Clinical Application Guangdong Weiliang Yuansu Kexue 2011, 18 (9) 1-31
18. Wallwey, C.; Li, S.-M. Ergot Alkaloids: Structure Diversity, Biosynthetic Gene Clusters and Functional Proof of Biosynthetic Genes Nat. Prod. Rep. 2011, 28, 496-510
19. Wang, X.; Guo, Z. Targeting and Delivery of Platinum-Based Anticancer Drugs Chem. Soc. Rev. 2013, 42, 202-224
20. Graf, N.; Lippard, S. J. Redox Activation of Metal-Based Prodrugs as a Strategy for Drug Delivery Adv. Drug Delivery Rev. 2012, 64, 993-1004
21. For a recent discussion of obscure elements in pharmaceuticals, consult the following: Sekhon, B. S. Inorganics/Bioinorganics: Biological, Medicinal and Pharmaceutical Uses J. Pharm. Educ. Res. 2011, 2, 1-20
22. Bhabak, K. P.; Bhuyan, B. J.; Mugesh, G. Bioinorganic and Medicinal Chemistry: Aspects of Gold(I)-Protein Complexes Dalton Trans. 2011, 40, 2099-2111
23. Berners-Price, S. J.; Filipovska, A. Gold Compounds as Therapeutic Agents for Human Diseases Metallomics 2011, 3, 863-873
24. Bschor, T. Lithium in the Treatment of Major Depressive Disorder Drugs 2014, 74, 855-862
25. Smoum, R.; Rubinstein, A.; Dembitsky, V. M.; Srebnik, M. Boron Containing Compounds as Protease Inhibitors Chem. Rev. 2012, 112, 4156-4220
26. Newman, D. J.; Cragg, G. M. Natural Products as Sources of New Drugs over the 30 Years from 1981 to 2010 J. Nat. Prod. 2012, 75, 311-335
27. Cardinal Health. FDA-Approved Radiopharmaceuticals and Formulary. http://www.cardinal.com/us/en/nuclearmedicinecompliance/fdaapproved (accessed July 18, 2014).